CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Prelude Therapeutics Fiscal Q4 2025 Earnings Report | CapyFin

Prelude Therapeutics

PRLD · NASDAQ🇺🇸

Overview Earnings

Dividends Seasonality Metrics

Q4 2025 Q3 2025 +10.69%Q2 2025 +0.83%Q1 2025 -4.07%Q4 2024 +4.14%Q3 2024 -1.55%Q2 2024 +21.57%Q1 2024 -6.27%Q4 2023 +36.98%Q3 2023 +30.77%Q2 2023 -2.13%Q1 2023 -3.84%Q4 2022 +9.15%Q3 2022 -8.24%Q2 2022 +21.68%Q1 2022 +1.00%Q4 2021 +16.92%Q3 2021 -5.43%Q2 2021 -5.33%Q1 2021 +8.85%Q4 2020 -2.58%Q3 2020 -3.37%Q2 2020 Q1 2020 Q4 2019 Q3 2019 Q2 2019 Q1 2019

Mar 09

Prelude Therapeutics Q4 2025 Earnings Report

Estimated Revenue:$20.5M

Estimated EPS:-$0.24

+48.9% YoY

Prelude Therapeutics

Unlock previous datapoints

Prelude Therapeutics

Unlock previous datapoints

Loading...

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Prelude Therapeutics

Key Statistics

Market Cap

$159M

P/E Ratio

-1.98

Sector

N/A

Industry

N/A

52-Week High

$3.86

52-Week Low

$0.615